DEPACON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Depacon, and what generic alternatives are available?
Depacon is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in DEPACON is valproate sodium. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the valproate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depacon
A generic version of DEPACON was approved as valproate sodium by SAGENT on November 14th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEPACON?
- What are the global sales for DEPACON?
- What is Average Wholesale Price for DEPACON?
Summary for DEPACON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 112 |
| Clinical Trials: | 7 |
| Patent Applications: | 4,551 |
| Drug Prices: | Drug price information for DEPACON |
| DailyMed Link: | DEPACON at DailyMed |
Recent Clinical Trials for DEPACON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cerebral Therapeutics LLC | Phase 1/Phase 2 |
| Neuroscience Trials Australia | Phase 1/Phase 2 |
| Barretos Cancer Hospital | Early Phase 1 |
US Patents and Regulatory Information for DEPACON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | DEPACON | valproate sodium | INJECTABLE;INJECTION | 020593-001 | Dec 30, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
